Sunday, July 20, 2025 7/20/2025

DoseRT™ : A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification

Award Number: R44CA232879
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2018
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

DoseRT™ : A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification - ABSTRACT Radiation therapy (RT) is a curative treatment, used adjuvant to surgery and chemotherapy in over 60% of cancers. It is delivered to nearly 1 out of every 6 people at some point in their lifetime. External beam treatment is commonly fractionated (i.e., delivered in 25-40 daily fractions), although there is a trend towards hypofractionation (5-10 days) with higher doses per fraction. While RT is generally considered safe and effective, it is well known that minor deviations in treatment happen on a daily basis in a busy treatment facility, and these changes are prone to higher human error rates. Major potential side effects can occur if not administered with high daily accuracy, and the precision needed is at the millimeter level in patient and beam alignment, in order to keep normal tissue doses sufficiently low. However, there is a proven 1-5% incidence of secondary cancer from this treatment. This is particularly relevant in whole breast radiotherapy, where even 2% target dose delivery (1Gy) to part of the contralateral breast has been proven to lead to a high probability for a secondary cancer. In reality, no clinic actually knows their true incident rate, because no system exists to visualize every treatment as part of routine clinical practice. DoseOptics’ invention of Cherenkov imaging, branded as BeamSite™, provides time-gated single photon video rate imaging of the light coming off tissue during the radiation dose delivery as it happens. The parent Phase II grant for this proposal, funded development of Cherenkov imaging with the VisionRT surface guided radiotherapy system (SGRT) system. Together the combined system has been trademarked as DoseRTTM, where the Cherenkov video of dose delivery is displayed in the same window monitor as the SGRT metrics of patient position. This combined interface provides a complete intuitive package for the therapists, where daily assessment and corrections can be made as needed. VisionRT and DoseOptics have a signed a long-term partnership and license and finance agreement. In this Phase IIB application, key improvements are implemented from test use, to make DoseRT more commercially viable for widespread deployment across different vendor platforms, more easily used by various therapy teams, and with some customization approaches for each center. The project is based upon previous NIH supported hardware that is now FDA 510(k) cleared. Aims 1 & 2 advance strategic updates to hardware and software systems for which improve cost structure and robustness, improving commercial viability of the system. This updated system will also be 510(k) cleared in Aim 3 with beta deployment. The project will culminate in Aim 4 with broader deployment and testing validation with an image registry. This clinical registry data will be used to validate marketing claims around incident detection and improved radiotherapy delivery by visualization of the beam on the patient. The team involved encompasses the two companies with expertise across all areas of development, as well as a number of clinical partner sites. The company has secured third-party investment for the Phase IIB matching funds. This project will complete commercialization readiness of DoseRT for a customer-ready solution.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $998,974 )
2025	2025	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Treatment Research	000	5	5/30/2025	NON-COMPETING CONTINUATION	$998,974
														Subtotal = $998,974

Issue Date FY: 2024 ( Subtotal = $998,974 )
2024	2024	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Treatment Research	000	4	6/13/2024	COMPETING CONTINUATION	$998,974
														Subtotal = $998,974

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	000	3	3/18/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	000	3	6/14/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $1,000,000 )
2020	2020	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	001	3	5/27/2020	NON-COMPETING CONTINUATION	$1,000,000
2020	2018	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	000	1	11/25/2019	NEW	$0
														Subtotal = $1,000,000

Issue Date FY: 2019 ( Subtotal = $1,000,000 )
2019	2019	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	001	2	5/22/2019	EXTENSION WITH OR WITHOUT FUNDS	$1,000,000
2019	2018	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	000	1	5/21/2019	NEW	$0
														Subtotal = $1,000,000

Issue Date FY: 2018 ( Subtotal = $252,666 )
2018	2018	DOSEOPTICS LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Cancer Cause and Prevention Research	000	1	8/1/2018	NEW	$252,666
														Subtotal = $252,666

Grand Total All Awards = $4,250,614

Top

All Categories

About

Search

Reports

Data Submission

Award Information

DoseRT™ : A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification

Award Number: R44CA232879

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2018

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer